A history of male contraceptive development – as experienced and related by our founder Elaine Lissner – was recently covered in a Priceonomics article called “The
The Telegraph announced that only one in 10 British men would take a male birth control pill when it is available. This finding is opposite
The publication on a study addressing treatment for enlarged prostate sponsored by Parsemus Foundation is one of the highest ranked articles in The Prostate. Due to
A recent study on dogs offers hope for treating enlarged prostate (technically known as benign prostatic hyperplasia or BPH). Recently published in the online version of The Prostate, researchers
The Medical Daily published a comprehensive news article on the development of male contraceptives, highlighting Vasalgel’s journey to market. Journalist Stephanie Castillo interviewed Parsemus Foundation’s
Evidence is mounting that hormone therapy (HT) after menopause is not associated with increased risks, despite earlier concerns. A recent meta-analysis of a number of
The topic of male contraception was covered in an article by Kristen Fawcett for US News and World Report. Vasalgel and Clean Sheets Pill were
Vasalgel has enjoyed significant media presence recently which is continuing into 2015. The Santa Fe Reporter highlighted the advancements that Vasalgel promises to bring to
Elaine Lissner, Director of Parsemus Foundation, was interviewed by ABC TV news – San Francisco. The piece focused on the development of Vasalgel and aired
Common birth control pills called combined oral contraceptives (COC) contain ethinyl-estradiol, a derivative of the estradiol found in the body. COCs are known to raise
And if you don’t find a match there, this slightly more complex clinical trials finder includes studies sponsored by companies as well:
